Biomarker analysis from phase I/II study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Gazzah, A. [1 ]
Lee, J. S. [2 ]
Wang, E. [2 ]
Ternes, N. [3 ]
Wang, H. [2 ]
Boitier, E. [3 ]
Lartigau, A. [3 ]
Chadjaa, M. [3 ]
Dib, C. [3 ]
Muzard, G. [3 ]
Valence, S. [3 ]
Remaury, A. [3 ]
Palu, C. C. [4 ]
Bauchet, A-L. [3 ]
机构：
[1] Gustave Roussy, Drug Dev Dept, Villejuif, France
[2] Sanofi, Cambridge, MA USA
[3] Sanofi, Paris, France
[4] Sanofi, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
71P
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [41] Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC):: a phase I trial
    Krajnik, G
    Wein, W
    Greil, R
    Marhold, F
    Mohn-Staudner, A
    Kummer, F
    Malayeri, R
    Zöchbauer-Müller, S
    Huber, H
    Pirker, R
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) : 1977 - 1980
  • [42] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Leighl, N. B.
    Soria, J.
    Bennouna, J.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] BEVACIZUMAB BEYOND PROGRESSION IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY RESULTS OF A PHASE II STUDY
    Timmer-Bonte, Johanna N. H.
    Van den Hurk, Desiree G. M.
    Dohmen, Miriam A.
    Smits-Vandergraaf, Chantal A.
    Van der Drift, Miep
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1255 - S1256
  • [44] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Soria, J. C.
    Bennouna, J.
    Leighl, N.
    Khuri, F.
    Traynor, A. M.
    Johnson, B.
    Kay, A.
    Blais, N.
    Jehl, V.
    Papadimitrakopoulou, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 559
  • [45] Phase II study of vinorelbine (VNR) and gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC)
    Firvida, JL
    Rodriguez, R
    Sabin, P
    Castellanos, J
    Mata, JG
    Salgado, M
    Vazquez, S
    Lazaro, M
    Delgado, FM
    ANNALS OF ONCOLOGY, 1998, 9 : 97 - 97
  • [46] Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Ramalingam, S.
    Schreeder, M.
    Steis, R.
    Guidice, R.
    Marshland, T.
    Butler, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
    Bertino, Erin M.
    Bekaii-Saab, Tanios
    Fernandez, Soledad
    Diasio, Robert B.
    Karim, Nagla A.
    Otterson, Gregory A.
    Villalona-Calero, Miguel A.
    LUNG CANCER, 2013, 79 (01) : 27 - 32
  • [48] Three agents chemotherapy (GEP) in advanced non-small cell lung cancer (NSCLC): A phase II study
    Ferrari, Vittorio D.
    Fogazzi, Gianluca
    Marini, Giovanni
    Caprioli, Alberto
    Bozzola, Giordano
    Nava, Anna Maria
    Tassi, GianFranco
    ANNALS OF ONCOLOGY, 2006, 17 : 228 - 228
  • [49] Phase I study of gemcitabine (GEM) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC).
    Kawabata, S
    Oka, M
    Fukuda, M
    Kinoshita, A
    Fukuda, M
    Nagashima, S
    Nakamura, Y
    Nakano, H
    Soda, H
    Kohno, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 688S - 688S
  • [50] A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)
    Theriau, Christopher F.
    Feng, Jamie
    Eng, Lawson
    Shepherd, Frances A.
    DeCarolis, Mary
    Glenns, Vivian
    Kulkarni, Swati
    VanderMeer, Rachel
    Zurawska-Fortin, Urszula
    Hao, Desiree
    Le, Lisa
    Wozniczka, Isabel
    Al-Kindy, Aida
    Xie, Danny
    Zhang, Tong
    Subramanian, Vasanth
    Stockley, Tracy
    Bradbury, Penelope A.
    Liu, Geoffrey
    Leighl, Natasha B.
    CANCER RESEARCH, 2023, 83 (08)
12345